This study showed significant improvement in metabolic abnormalities linked to lipodystrophy and low baseline leptin levels, registered both in the short (1 year) and long term (mean, 5 years), with the overall result of patients’ quality of life amelioration. This evidence concerns the gene LEP and lipodystrophy.